149 related articles for article (PubMed ID: 792847)
21. Antithymocyte globulin therapy after renal transplantation at the Massachusetts General Hospital.
Delmonico FL
Transplant Proc; 1984 Aug; 16(4):979-82. PubMed ID: 6380062
[No Abstract] [Full Text] [Related]
22. Rabbit anti-thymocyte globulin treatment of steroid resistant rejection in renal allograft recipients immunosuppressed with cyclosporine A.
O'Donoghue DJ; Johnson RW; Mallick NP; Gokal R; Ballardie FW; Bakran A; Pearson R; Scott P
Transplant Proc; 1989 Feb; 21(1 Pt 2):1736-7. PubMed ID: 2652568
[No Abstract] [Full Text] [Related]
23. [Canadian project of antilymphocytic globulin experimentation in kidney transplantation].
Taylor HE
Union Med Can; 1971 Jan; 100(1):136-41. PubMed ID: 4926001
[No Abstract] [Full Text] [Related]
24. Superior renal allograft survival and decreased rejection with early high-dose and sequential multi-species antilymphocyte globulin therapy.
Thomas F; Cunningham P; Thomas J; Gross U; Gaskins D; Sash C; Parker K
Transplant Proc; 1987 Feb; 19(1 Pt 3):1874-8. PubMed ID: 3547892
[No Abstract] [Full Text] [Related]
25. The value of ALG and ATG in clinical renal transplantation--recent European experience.
Groth CG
Transplant Proc; 1981 Mar; 13(1 Pt 1):460-1. PubMed ID: 7022873
[No Abstract] [Full Text] [Related]
26. Human gamma globulin enhances the survival of renal allografts.
Riggio RR; Cheigh JS; Suthanthiran M; Stubenbord WT; Fotino M; Haschmeyer RH; Stenzel KH; Rubin AL
Proc Eur Dial Transplant Assoc; 1979; 16():426-30. PubMed ID: 95048
[TBL] [Abstract][Full Text] [Related]
27. Antithymocyte globulin (ATG) dosage and graft survival in renal transplantation.
Kountz SL; Butt KH; Rao TK; Zielinski CM; Rafi M; Schultz JR
Transplant Proc; 1977 Mar; 9(1):1023-5. PubMed ID: 325728
[No Abstract] [Full Text] [Related]
28. 20-year follow-up results of a randomized controlled trial comparing antilymphocyte globulin induction to no induction in renal transplant patients.
Cantarovich M; Durrbach A; Hiesse C; Ladouceur M; Benoit G; Charpentier B
Transplantation; 2008 Dec; 86(12):1732-7. PubMed ID: 19104413
[TBL] [Abstract][Full Text] [Related]
29. Beneficial effect of concomitant induction with antilymphoblast globulin, cyclosporine, and steroids on long-term renal allograft outcome.
Koga A; Moreso FJ; Seron D; Gil-Vernet S; Cruzado JM; Castelao AM; Grinyó JM
Transplant Proc; 2004 Jun; 36(5):1305-7. PubMed ID: 15251318
[TBL] [Abstract][Full Text] [Related]
30. Do prophylactic antilymphocyte globulins (ALG and OKT3) improve renal transplant survival in recipient and donor high-risk groups?
Cecka JM; Gjertson D; Terasaki PI
Transplant Proc; 1993 Feb; 25(1 Pt 1):548-9. PubMed ID: 8438408
[No Abstract] [Full Text] [Related]
31. Improved cadaveric kidney graft survival with initiation of antilymphocyte globulin pretransplant in patients with a positive flow cytometry crossmatch.
Hong JH; Sadeghian M; Sumrani N; Cacciarelli TV; Distant DA; Sommer BG; Norin AJ
Transplant Proc; 1996 Jun; 28(3):1340-1. PubMed ID: 8658685
[No Abstract] [Full Text] [Related]
32. [The clinical use of antilymphocyte globulin (ALG) (author's transl)].
Brendel W; Seifert J; Ring J
MMW Munch Med Wochenschr; 1975 Aug; 117(35):1361-8. PubMed ID: 809676
[TBL] [Abstract][Full Text] [Related]
33. The impact of quadruple versus triple drug immunosuppression on clinical results of cadaver renal transplantation.
Rao KV; Andersen RC
Transplant Proc; 1989 Feb; 21(1 Pt 2):1652. PubMed ID: 2652540
[No Abstract] [Full Text] [Related]
34. Single center experience of the effect of delayed function on outcome in retransplant recipients of cadaveric renal allografts.
Langley J; Vergne-Marini P; Dickerman RM; Brinker KR; Land G
Transplant Proc; 1991 Apr; 23(2):1757-9. PubMed ID: 2053145
[TBL] [Abstract][Full Text] [Related]
35. [Antilymphocytic serum (antilymphocyte globulin) in the management of transplants].
Gieldanowski J
Wiad Lek; 1970 Nov; 23(22):1971-7. PubMed ID: 4395160
[No Abstract] [Full Text] [Related]
36. Association of sensitization to horse antilymphocyte/thymocyte globulin with recipient age and decreased renal allograft survival rates.
Filo RS; Book B; Pescovitz MD; Milgrom ML; Leapman SB
Transplant Proc; 1993 Feb; 25(1 Pt 1):577-80. PubMed ID: 8438421
[No Abstract] [Full Text] [Related]
37. [Experiences with antilymphocyte globulin in kidney transplants].
Largiadèr F; Linder E; Scheitlin W; Senning A
Helv Chir Acta; 1970 Apr; 37(1):34-9. PubMed ID: 4939948
[No Abstract] [Full Text] [Related]
38. [Use and limits of preventive antilymphocyte globulin therapy following kidney transplantation. A prospective randomized study].
Grundmann R; Wienand P; Meider G; Vlaho V; Pichlmaier H
Klin Wochenschr; 1984 Oct; 62(20):979-85. PubMed ID: 6389973
[TBL] [Abstract][Full Text] [Related]
39. A prospective randomized comparison of prophylactic ALG and OKT3 in cadaver kidney allograft recipients.
Hanto DW; Jendrisak MD; McCullough CS; So SK; Marsh JW; Rush T; Michalski S; Phelan D; Mohanakumar T
Transplant Proc; 1991 Feb; 23(1 Pt 2):1050-1. PubMed ID: 1899150
[No Abstract] [Full Text] [Related]
40. Renal transplant survival, the HL-A system, and antilymphocyte serum therapy: report of some data collected for a recent conference.
Corry RJ
Transplant Proc; 1972 Sep; 4(3):401-5. PubMed ID: 4562766
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
